|
1
|
Yan P, Xu Z, Hui X, Chu X, Chen Y, Yang C, Xu S, Cui H, Zhang L, Zhang W, Wang L, Zou Y, Ren Y, Liao J, Zhang Q, Yang K, Zhang L, Liu Y, Li J, Yang C, Yao Y, Liu Z, Jiang X, Zhang B. The reporting quality and methodological quality of dynamic prediction models for cancer prognosis. BMC Med Res Methodol 2025; 25:58. [PMID: 40025462 PMCID: PMC11872325 DOI: 10.1186/s12874-025-02516-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2024] [Accepted: 02/20/2025] [Indexed: 03/04/2025] Open
Abstract
BACKGROUND To evaluate the reporting quality and methodological quality of dynamic prediction model (DPM) studies on cancer prognosis. METHODS Extensive search for DPM studies on cancer prognosis was conducted in MEDLINE, EMBASE, and the Cochrane Library databases. The Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis (TRIPOD) and the Prediction model Risk of Bias Assessment Tool (PROBAST) were used to assess reporting quality and methodological quality, respectively. RESULTS A total of 34 DPM studies were identified since the first publication in 2005, the main modeling methods for DPMs included the landmark model and the joint model. Regarding the reporting quality, the median overall TRIPOD adherence score was 75%. The TRIPOD items were poorly reported, especially the title (23.53%), model specification, including presentation (55.88%) and interpretation (50%) of the DPM usage, and implications for clinical use and future research (29.41%). Concerning methodological quality, most studies were of low quality (n = 30) or unclear (n = 3), mainly due to statistical analysis issues. CONCLUSIONS The Landmark model and joint model show potential in DPM. The suboptimal reporting and methodological qualities of current DPM studies should be improved to facilitate clinical application.
Collapse
Affiliation(s)
- Peijing Yan
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
- Clinical Research Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China
| | - Zhengxing Xu
- Department of Epidemiology and Health Statistics, School of Public Health, Southwest Medical University, Luzhou, Sichuan, China
| | - Xu Hui
- Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, Gansu, China
- Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China
| | - Xiajing Chu
- Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, ON, Canada
| | - Yizhuo Chen
- The Second Clinical Medical Hospital, Lanzhou University, Lanzhou, Gansu, China
| | - Chao Yang
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Shixi Xu
- Department of Preventive Medicine, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Huijie Cui
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Li Zhang
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Wenqiang Zhang
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Liqun Wang
- Department of Hygienic Toxicology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Yanqiu Zou
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Yan Ren
- Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Jiaqiang Liao
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Qin Zhang
- Department of Occupational and Environmental Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Kehu Yang
- Evidence Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou, Gansu, China
- Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China
- Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, Gansu, China
| | - Ling Zhang
- Department of Iatrical Polymer Material and Artificial Apparatus, School of Polymer Science and Engineering, Sichuan University, Chengdu, Sichuan, China
| | - Yunjie Liu
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Jiayuan Li
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Chunxia Yang
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Yuqin Yao
- Department of Hygienic Toxicology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China
| | - Zhenmi Liu
- Department of Maternal, Child and Adolescent Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
- West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 16, Section 3, South Renmin Road, Wuhou District, Chengdu, 610041, China.
| | - Xia Jiang
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Nutrition and Food Hygiene, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
- West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 16, Section 3, South Renmin Road, Wuhou District, Chengdu, 610041, China.
| | - Ben Zhang
- Department of Epidemiology and Biostatistics, Institute of Systems Epidemiology and West China-PUMC C. C. Chen Institute of Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Occupational and Environmental Health, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.
- West China School of Public Health and West China Fourth Hospital, Sichuan University, No. 16, Section 3, South Renmin Road, Wuhou District, Chengdu, 610041, China.
| |
Collapse
|
|
2
|
Russo D, Mariani P, Caponio VCA, Lo Russo L, Fiorillo L, Zhurakivska K, Lo Muzio L, Laino L, Troiano G. Development and Validation of Prognostic Models for Oral Squamous Cell Carcinoma: A Systematic Review and Appraisal of the Literature. Cancers (Basel) 2021; 13:cancers13225755. [PMID: 34830913 PMCID: PMC8616042 DOI: 10.3390/cancers13225755] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Revised: 11/08/2021] [Accepted: 11/13/2021] [Indexed: 12/23/2022] Open
Abstract
(1) Background: An accurate prediction of cancer survival is very important for counseling, treatment planning, follow-up, and postoperative risk assessment in patients with Oral Squamous Cell Carcinoma (OSCC). There has been an increased interest in the development of clinical prognostic models and nomograms which are their graphic representation. The study aimed to revise the prognostic performance of clinical-pathological prognostic models with internal validation for OSCC. (2) Methods: This systematic review was performed according to the Cochrane Handbook for Diagnostic Test Accuracy Reviews chapter on searching, the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines, and the Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies (CHARMS). (3) Results: Six studies evaluating overall survival in patients with OSCC were identified. All studies performed internal validation, while only four models were externally validated. (4) Conclusions: Based on the results of this systematic review, it is possible to state that it is necessary to carry out internal validation and shrinkage to correct overfitting and provide an adequate performance for optimism. Moreover, calibration, discrimination and nonlinearity of continuous predictors should always be examined. To reduce the risk of bias the study design used should be prospective and imputation techniques should always be applied to handle missing data. In addition, the complete equation of the prognostic model must be reported to allow updating, external validation in a new context and the subsequent evaluation of the impact on health outcomes and on the cost-effectiveness of care.
Collapse
Affiliation(s)
- Diana Russo
- Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania “Luigi Vanvitelli”, 80122 Napoli, Italy; (D.R.); (P.M.); (L.L.)
| | - Pierluigi Mariani
- Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania “Luigi Vanvitelli”, 80122 Napoli, Italy; (D.R.); (P.M.); (L.L.)
| | - Vito Carlo Alberto Caponio
- Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (V.C.A.C.); (L.L.R.); (K.Z.); (L.L.M.)
| | - Lucio Lo Russo
- Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (V.C.A.C.); (L.L.R.); (K.Z.); (L.L.M.)
| | - Luca Fiorillo
- Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, Messina University, 98122 Messina, Italy;
| | - Khrystyna Zhurakivska
- Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (V.C.A.C.); (L.L.R.); (K.Z.); (L.L.M.)
| | - Lorenzo Lo Muzio
- Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (V.C.A.C.); (L.L.R.); (K.Z.); (L.L.M.)
- Consorzio Interuniversitario Nazionale per la Bio-Oncologia (C.I.N.B.O.), 66100 Chieti, Italy
| | - Luigi Laino
- Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania “Luigi Vanvitelli”, 80122 Napoli, Italy; (D.R.); (P.M.); (L.L.)
| | - Giuseppe Troiano
- Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy; (V.C.A.C.); (L.L.R.); (K.Z.); (L.L.M.)
- Correspondence: ; Tel.: +39-34889-86409; Fax: +39-0881-588081
| |
Collapse
|
|
3
|
Rahman SA, Maynard N, Trudgill N, Crosby T, Park M, Wahedally H, Underwood TJ, Cromwell DA. Prediction of long-term survival after gastrectomy using random survival forests. Br J Surg 2021; 108:1341-1350. [PMID: 34297818 PMCID: PMC10364915 DOI: 10.1093/bjs/znab237] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 06/03/2021] [Indexed: 12/24/2022]
Abstract
BACKGROUND No well validated and contemporaneous tools for personalized prognostication of gastric adenocarcinoma exist. This study aimed to derive and validate a prognostic model for overall survival after surgery for gastric adenocarcinoma using a large national dataset. METHODS National audit data from England and Wales were used to identify patients who underwent a potentially curative gastrectomy for adenocarcinoma of the stomach. A total of 2931 patients were included and 29 clinical and pathological variables were considered for their impact on survival. A non-linear random survival forest methodology was then trained and validated internally using bootstrapping with calibration and discrimination (time-dependent area under the receiver operator curve (tAUC)) assessed. RESULTS The median survival of the cohort was 69 months, with a 5-year survival of 53.2 per cent. Ten variables were found to influence survival significantly and were included in the final model, with the most important being lymph node positivity, pT stage and achieving an R0 resection. Patient characteristics including ASA grade and age were also influential. On validation the model achieved excellent performance with a 5-year tAUC of 0.80 (95 per cent c.i. 0.78 to 0.82) and good agreement between observed and predicted survival probabilities. A wide spread of predictions for 3-year (14.8-98.3 (i.q.r. 43.2-84.4) per cent) and 5-year (9.4-96.1 (i.q.r. 31.7-73.8) per cent) survival were seen. CONCLUSIONS A prognostic model for survival after a potentially curative resection for gastric adenocarcinoma was derived and exhibited excellent discrimination and calibration of predictions.
Collapse
Affiliation(s)
- S A Rahman
- School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
| | - N Maynard
- Oxford University Hospitals NHS Trust, Oxford, UK
| | - N Trudgill
- Sandwell and West Birmingham NHS Trust, Birmingham, UK
| | - T Crosby
- Velindre Cancer Centre, Cardiff, UK
| | - M Park
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
| | - H Wahedally
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
| | - T J Underwood
- School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
| | - D A Cromwell
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK
| |
Collapse
|
|
4
|
Puhr HC, Reiter TJ, El-Mahrouk M, Saliternig L, Wolf P, Mair MJ, Steindl A, Paireder M, Asari R, Schoppmann SF, Berghoff AS, Preusser M, Ilhan-Mutlu A. Thyroid Hormone Replacement Therapy Is Associated with Longer Overall Survival in Patients with Resectable Gastroesophageal Cancer: A Retrospective Single-Center Analysis. Cancers (Basel) 2021; 13:5050. [PMID: 34680197 PMCID: PMC8534173 DOI: 10.3390/cancers13205050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 09/30/2021] [Accepted: 10/06/2021] [Indexed: 12/24/2022] Open
Abstract
INTRODUCTION As thyroid hormones modulate proliferative pathways it is surmised that they can be associated with cancer development. Since the potential association of gastroesophageal cancer and thyroid disorders has not been addressed so far, the aim of this study was to investigate the association of thyroid hormone parameters with the outcome of these patients, so novel prognostic and even potentially therapeutic markers can be defined. MATERIAL AND METHODS Clinical and endocrinological parameters of patients with resectable gastroesophageal cancer treated between 1990 and 2018 at the Vienna General Hospital, Austria, including history of endocrinological disorders and laboratory analyses of thyroid hormones at first cancer diagnosis were investigated and correlated with the overall survival (OS). RESULTS In a total of 865 patients, a tendency towards prolonged OS in hypothyroid patients (euthyroid, n = 647: median OS 29.7 months; hyperthyroid, n = 50: 23.1 months; hypothyroid, n = 70: 47.9 months; p = 0.069) as well as a significant positive correlation of thyroid hormone replacement therapy with the OS was observed (without, n = 53: median OS 30.6 months; with, n = 67: 51.3 months; p = 0.017). Furthermore, triiodothyronine (T3) levels were also associated with the OS (median OS within the limit of normal: 23.4, above: 32.4, below: 9.6 months; p = 0.045). CONCLUSIONS Thyroid disorders and their therapeutic interventions might be associated with the OS in patients with resectable gastroesophageal cancer. As data on the correlation of these parameters is scarce, this study proposes an important impulse for further analyses concerning the association of thyroid hormones with the outcome in patients with gastroesophageal tumors.
Collapse
Affiliation(s)
- Hannah C. Puhr
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| | - Thorsten J. Reiter
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| | - Mohamed El-Mahrouk
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| | - Lena Saliternig
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| | - Peter Wolf
- Department of Medicine III, Division of Endocrinology and Metabolism, Medical University of Vienna, 1090 Vienna, Austria;
| | - Maximilian J. Mair
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| | - Ariane Steindl
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| | - Matthias Paireder
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
- Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria
| | - Reza Asari
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
- Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria
| | - Sebastian F. Schoppmann
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
- Department of Surgery, Medical University of Vienna, 1090 Vienna, Austria
| | - Anna S. Berghoff
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| | - Matthias Preusser
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| | - Aysegül Ilhan-Mutlu
- Department of Medicine I, Division of Oncology, Medical University of Vienna, 1090 Vienna, Austria; (H.C.P.); (T.J.R.); (M.E.-M.); (L.S.); (M.J.M.); (A.S.); (A.S.B.); (M.P.)
- Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria; (M.P.); (R.A.); (S.F.S.)
| |
Collapse
|
|
5
|
Palazón-Bru A, Martín-Pérez F, Mares-García E, Beneyto-Ripoll C, Gil-Guillén VF, Pérez-Sempere Á, Carbonell-Torregrosa MÁ. A general presentation on how to carry out a CHARMS analysis for prognostic multivariate models. Stat Med 2020; 39:3207-3225. [PMID: 32583899 DOI: 10.1002/sim.8660] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Revised: 01/27/2020] [Accepted: 05/18/2020] [Indexed: 12/19/2022]
Abstract
The CHARMS (critical appraisal and data extraction for systematic reviews of prediction modelling studies) checklist was created to provide methodological appraisals of predictive models, based on the best available scientific evidence and through systematic reviews. Our purpose is to give a general presentation on how to carry out a CHARMS analysis for prognostic multivariate models, making clear what the steps are and how they are applied individually to the studies included in the systematic review. This tutorial is aimed at providing such a resource. In addition to this explanation, we will apply the method to a real case: predictive models of atrial fibrillation in the community. This methodology could be applied to other predictive models using the steps provided in our review so as to have complete information for each included model and determine whether it can be implemented in daily clinical practice.
Collapse
Affiliation(s)
- Antonio Palazón-Bru
- Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain
| | | | - Emma Mares-García
- Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain
| | | | | | - Ángel Pérez-Sempere
- Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain
| | - María Ángeles Carbonell-Torregrosa
- Department of Clinical Medicine, Miguel Hernández University, Alicante, Spain.,Emergency Service, General University Hospital of Elda, Alicante, Spain
| |
Collapse
|
|
6
|
Leng X, Liu G, Wang S, Song J, Zhang W, Zhang X, Rong L, Ma Y, Song F. LINC01272 Promotes Migration and Invasion of Gastric Cancer Cells via EMT. Onco Targets Ther 2020; 13:3401-3410. [PMID: 32368096 PMCID: PMC7184168 DOI: 10.2147/ott.s242073] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 03/27/2020] [Indexed: 12/24/2022] Open
Abstract
PURPOSE Gastric cancer (GC) is the fifth most common tumor in the world, and most patients with GC have a poor prognosis. This study aimed to explore the biological influence and mechanism of LINC01272 in GC. MATERIALS AND METHODS Using bioinformatic analyses, we investigated the expression of LINC01272 in TCGA database and predicted the biological functions and mechanism of LINC01272 in GC. Then, we detected the expression of LINC01272 in GC cell lines, GC tissues, and corresponding normal tissues using real-time polymerase chain reaction (RT-PCR). Finally, we explored the migration and invasion ability of LINC01272 by wound-healing and Transwell assays and examined the expression of epithelial-mesenchymal transition (EMT)-related proteins through Western blotting. RESULTS We found that LINC01272 was upregulated in GC and was associated with GC staging and lymph node metastasis. The results of wound-healing and Transwell assays revealed that the LINC01272 was closely related to GC cell migration and invasion. LINC01272 knockdown inhibited the migration and invasion ability of GC cells by reducing the expression of EMT-related proteins. Overexpression of LINC01272 had the opposite effect. CONCLUSION Together, our results showed that LINC01272 promoted GC metastasis ability by regulating the expression of EMT-related proteins and could serve as a potential diagnostic biomarker for GC.
Collapse
Affiliation(s)
- Xue Leng
- Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing400016, People’s Republic of China
| | - Geli Liu
- Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing400016, People’s Republic of China
| | - Sen Wang
- Laboratory Department, Affiliated Hospital of Jining Medical College, Shandong, 272029, People’s Republic of China
| | - Jing Song
- Department of Bioinformatics, The Basic Medical School of Chongqing Medical University, Chongqing400016, People’s Republic of China
| | - Wanfeng Zhang
- Department of Bioinformatics, The Basic Medical School of Chongqing Medical University, Chongqing400016, People’s Republic of China
| | - Xianqin Zhang
- Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing400016, People’s Republic of China
| | - Li Rong
- Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing400016, People’s Republic of China
- Department of Gastroenterology, Chongqing Public Health Medical Center, Chongqing, 400036, People’s Republic of China
| | - Yongping Ma
- Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing400016, People’s Republic of China
| | - Fangzhou Song
- Molecular Medicine and Cancer Research Center, Chongqing Medical University, Chongqing400016, People’s Republic of China
| |
Collapse
|